CLN3 Antibody

What Is CLN3 Antibody?

CLN3 antibodies are immunological reagents designed to detect the CLN3 protein, a multi-pass transmembrane protein critical for lysosomal enzyme trafficking and autophagic lysosomal reformation (ALR) . Batten disease, caused by CLN3 mutations, is characterized by lysosomal dysfunction and neurodegeneration. Antibodies against CLN3 are used in techniques such as Western blot (WB), immunofluorescence (IF), and immunohistochemistry (IHC) to study its expression and subcellular dynamics .

Key Applications of CLN3 Antibodies

CLN3 antibodies are employed to:

• Localize CLN3: Revealing its dual presence in the Golgi apparatus (45 kDa precursor) and lysosomes (65–80 kDa mature form) .

• Study Trafficking Pathways: Identifying interactions with CI-M6PR, retromer complexes, and SNARE proteins critical for lysosomal enzyme sorting .

• Assess Disease Mechanisms: Linking CLN3 dysfunction to lysosomal enzyme mis-sorting and defective ALR in Batten disease models .

Tested Applications and Performance

Challenges in CLN3 Antibody Specificity

A major hurdle in CLN3 research is the lack of reliable antibodies. Studies demonstrate that many commercially available reagents fail to distinguish between wild-type (WT) and CLN3 knockout (KO) samples . For example:

• Non-Specific Binding: Antibodies targeting CLN3 often detect identical bands in WT and CLN3 KO mouse tissues .

• Validation Requirements: Rigorous controls (e.g., KO cell lines) are essential to confirm specificity .

Case Study: Antibody Cross-Reactivity

Breakthrough Research Enabled by Novel Antibodies

Recent studies using newly developed CLN3 antibodies have advanced understanding of its biological roles:

• Golgi-Lysosome Trafficking: A 2023 study using a custom anti-CLN3 antibody revealed that CLN3 shuttles between the Golgi and lysosomes, coordinating CI-M6PR recycling and lysosomal enzyme delivery .

• ALR Dysregulation: CLN3 depletion disrupts autophagic lysosomal reformation, while overexpression induces lysosomal tubulation and proto-lysosome generation .

Key Findings from Proteomic Analysis

Proteintech 67957-1-Ig (Mouse Monoclonal)2

• Applications: WB (1:5,000–1:50,000), ELISA

• Validated Cell Lines: HeLa, HepG2, A549

• Storage: -20°C in PBS with 50% glycerol

Proteintech 20386-1-AP (Rabbit Polyclonal)9

• Applications: WB (1:500–1:3,000), IHC (1:20–1:200), IF/ICC (1:10–1:100)

• Tissue Reactivity: Human brain, HepG2 cells

• Storage: -20°C with 0.02% sodium azide

Future Directions and Recommendations

• Antibody Validation: Use KO controls and orthogonal methods (e.g., immunoprecipitation) to confirm specificity .

• Therapeutic Insights: Targeting CLN3-mediated trafficking pathways could restore lysosomal function in Batten disease .